Wu Hao, Gong Mancheng, Yuan Runqiang
Department of Urology, Zhongshan People's Hospital, Zhongshan, China.
Indian J Cancer. 2024 Jan 1;61(1):193-199. doi: 10.4103/ijc.ijc_211_24. Epub 2024 May 2.
The relationship between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in peripheral blood and prognosis after castration therapy for prostate cancer remains unclear.
A total of 186 patients with prostate cancer treated between January 2018 and March 2021 were selected as the study subjects. All patients underwent castration therapy. Patient follow-up records for 2 years were examined to assess progression-free survival. NLR, PLR, and PSA levels were measured in the participants' blood. Logistic regression analysis was used to identify factors affecting the occurrence of castration-resistant prostate cancer. Kaplan-Meier survival curves were plotted to analyze progression-free survival, and ROC curves were plotted to assess the predictive value of NLR and PLR for progression-free survival.
In the stable group, NLR, PLR, PSA levels, bone metastasis ratio, and Gleason score ≥8 were significantly lower than in the progression group. T3 stage, N0 stage, and M0 stage were significantly higher in the progression group, with statistical significance (P < 0.05). NLR, PLR, and PSA levels were all significantly linearly correlated (P < 0.05). High NLR, high PLR, high PSA, high bone metastasis, Gleason score <8, T3 stage, and N0 stage were independent risk factors for poor prognosis after castration therapy for prostate cancer, with statistical significance (P < 0.05). Patients with low NLR had significantly better progression-free survival than the high NLR group, and patients with low PLR had significantly better progression-free survival than the high PLR group, with statistical significance (P < 0.05). The area under the curve for NLR and PLR in predicting progression-free survival after castration therapy for prostate cancer was both greater than 0.90, indicating high clinical utility.
Peripheral blood NLR and PLR after castration therapy for prostate cancer are highly correlated with patient prognosis quality and can serve as important potential indicators for predicting patient prognosis quality.
外周血中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）与前列腺癌去势治疗后的预后之间的关系尚不清楚。
选取2018年1月至2021年3月期间接受治疗的186例前列腺癌患者作为研究对象。所有患者均接受去势治疗。检查患者2年的随访记录以评估无进展生存期。测量参与者血液中的NLR、PLR和PSA水平。采用逻辑回归分析确定影响去势抵抗性前列腺癌发生的因素。绘制Kaplan-Meier生存曲线以分析无进展生存期，并绘制ROC曲线以评估NLR和PLR对无进展生存期的预测价值。
稳定组的NLR、PLR、PSA水平、骨转移率和Gleason评分≥8均显著低于进展组。进展组的T3期、N0期和M0期显著更高，具有统计学意义（P<0.05）。NLR、PLR和PSA水平均呈显著线性相关（P<0.05）。高NLR、高PLR、高PSA、高骨转移、Gleason评分<8、T3期和N0期是前列腺癌去势治疗后预后不良的独立危险因素，具有统计学意义（P<0.05）。NLR低的患者无进展生存期明显优于NLR高的组，PLR低的患者无进展生存期明显优于PLR高的组，具有统计学意义（P<0.05）。NLR和PLR预测前列腺癌去势治疗后无进展生存期的曲线下面积均大于0.90，表明具有较高的临床实用性。
前列腺癌去势治疗后的外周血NLR和PLR与患者预后质量高度相关，可作为预测患者预后质量的重要潜在指标。
